Formosa Pharmaceuticals News
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery.
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the second of the two pivotal …
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol …
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
TAIPEI, May 12, 2022 /PRNewswire/ — Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the first of …
Formosa Pharmaceuticals and EirGenix establish a co-development alliance to develop TSY-0110 / EG12043 (ado-trastuzumab emtansine biosimilar) for HER2-positive breast cancer.
TAIPEI, Taiwan, March 24, 2022 – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the approval of a resolution by the boards of directors of both Formosa Pharmaceuticals …
Formosa Pharmaceuticals announce registration on Emerging Stock Board of the Taipei Stock Exchange (TPEx)
TAIPEI – October 5, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code: 6838) announce its registration on the Emerging Stock Board of the Taipei Stock Exchange …
Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007
(Corticosteroid for inflammation and pain after cataract surgery) TAIPEI – June 3, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code:6838) and China Grand Pharma (“Grand”, HKG …
